In the changing environment of healthcare in the United States, Group Purchasing Organizations (GPOs) play an important role in access to medications and medical supplies. GPOs gather purchasing volumes to negotiate reduced prices for healthcare providers, mainly hospitals. With the three largest GPOs controlling about 90% of the market, their influence on the healthcare supply chain is significant. This article looks at the effect of GPOs on medication availability, including the concerning issue of drug shortages and how these organizations can encourage sustainable practices in healthcare.<\/p>\n
GPOs have a key function in the healthcare system by negotiating contracts with suppliers to secure lower prices for necessary medications and medical equipment. With over $250 billion in annual hospital purchases, GPOs have the ability to influence market conditions. While they aim to provide cost savings to healthcare providers, this sometimes presents challenges for manufacturers, especially generic drug producers.<\/p>\n
The ongoing issue of drug shortages is a growing worry in healthcare. Data indicates that nearly 300 essential treatments have been affected by a roughly 30% increase in new drug shortages over the past two years. One key example is albuterol, a vital medication for asthma patients, which has faced supply problems since summer 2022. The closure of Akorn Pharma, one of the main suppliers of liquid albuterol, left only one domestic manufacturer to meet demand.<\/p>\n
The purchasing strategies employed by GPOs greatly influence medication availability. By encouraging pharmaceutical manufacturers to offer lower prices, GPOs favor cost-saving contracts, which can unintentionally lead to market instability. Each time a non-competitive priced generic drug exits the market due to lack of sustainable profit margins, the risk of drug shortages increases. This creates a loop where fewer manufacturers remain to supply essential medications, greatly reducing options for healthcare providers and patients.<\/p>\n
The purchasing power held by GPOs results from a concentration of contracts with manufacturers capable of producing low-cost generics. While this can be beneficial for healthcare providers trying to save money, it poses significant challenges for drug manufacturers, particularly smaller companies. The pressure to keep prices and profit margins low can push smaller manufacturers out of the market, contributing to increasing drug shortages.<\/p>\n
In fact, the 2015 Bipartisan Budget Act placed penalties on low-cost generic drugs that are similar to those for brand-name medicines, creating artificial price ceilings. This regulatory structure complicates the ability of generic drug manufacturers to invest in production capabilities. As the investment potential decreases for these companies, competition in the market also decreases, leading to insufficient drug availability for healthcare facilities.<\/p>\n
Understanding the serious implications of GPO practices on drug shortages, the FDA and Congress have proposed several recommendations. The FDA has urged GPOs to guarantee sustainable returns for manufacturers, especially for those producing necessary medications. This can happen by creating contracts that reward quality production, thereby readjusting the economic incentives that currently disrupt the market.<\/p>\n
However, the history of GPOs shows a hesitance to change. The emphasis remains on securing low-cost contracts, which threatens medication availability. This situation has led to calls for governmental intervention to tackle the problems caused by GPOs, moving beyond mere acknowledgment to actionable solutions.<\/p>\n
MacKay Jimeson, a healthcare executive and the director of the Patient Access & Affordability Project at Patients Rising, has expressed concerns about the operational issues created by GPOs. Drawing from his experiences as a father of a child with asthma, he highlights how medication shortages can cause fear and worry among families relying on critical treatments. His viewpoint resonates within the larger conversation about the challenges GPOs pose to drug manufacturers, particularly smaller companies that lack sufficient capital. Jimeson has urged Congress to take prompt action to realign financial incentives in favor of sustainable drug manufacturing practices.<\/p>\n
GPOs have considerable influence, creating a monopolized purchasing environment that places extreme pressure on drug manufacturers. Such monopolization risks reducing competition, which has traditionally been key to a healthy marketplace. Smaller manufacturers may feel compelled to limit their offerings or leave the market completely, causing a noticeable decrease in the range of medications available to healthcare providers. This is particularly concerning for generics, which are intended to make essential medications affordable and accessible.<\/p>\n
Healthcare administrators and practice owners should understand these dynamics. Relying on GPOs for competitive prices can have unintended effects, ultimately impacting patient care and access to treatment. The troubling reality is that the financial motives driving both GPOs and drug manufacturers can lead to a healthcare system that leaves critical medications unavailable to those who need them most.<\/p>\n
<\/p>\n